0001413754 true 0001413754 2022-12-27 2022-12-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K/A

Amendment No. 1 to

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): April 26, 2023 (December 27, 2022)

 

MARIZYME, INC.

 

(Exact name of registrant as specified in its charter)

 

Nevada   000-53223   82-5464863

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

555 Heritage Drive, Suite 205, Jupiter, Florida   33458
(Address of principal executive offices)   (Zip Code)

 

(561) 935-9955

 

(Registrant’s telephone number, including area code)

 

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

 

Emerging Growth Company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Not applicable.        

 

 

 

 

 

 

EXPLANATORY NOTE

 

This Amendment No. 1 to the Current Report on Form 8-K of Marizyme Inc. (the “Company”) filed with the Securities and Exchange Commission on December 28, 2022 (the “Original Report”) is being filed to correct the report of voting results from the Company’s Annual Meeting of Shareholders that took place on December 27, 2022. In the Original Report, the votes of certain holders of convertible notes were counted because the convertible notes they are holding contain a provision (the “Voting Provision”) that entitles them to vote with the common stockholders on an as converted to common stock basis with respect to all corporate matters of the Company on which the holders of Common Stock are entitled to vote, without having converted their convertible notes into common stock. Although the Nevada Revised Statutes allow for this Voting Provision, this allowance is conditioned on the Company’s articles of incorporation containing the Voting Provision and the Company’s articles of incorporation, as currently amended and restated (the “Articles”), do not contain that provision. The Company will endeavor to amend the Articles to include the Voting Provision going forward.

 

Item 5.07 Submission of Matters to a Vote of Security Holders

 

On December 27, 2022, Marizyme, Inc. (the “Company”) held its Annual Meeting of Shareholders virtually via live audio webcast at https://agm.issuerdirect.com/mrzm. A total of 20,964,240 shares of common stock representing 51.73% of the aggregate shares outstanding and eligible to vote and constituting a quorum were represented in person or by valid proxies at the annual meeting.

 

David Barthel, Terry Brostowin, Esq., Dr. William Hearl, Julie Kampf, Dr. Vithalbhai Dhaduk, Michael Stewart, and Dr. Nilesh Patel were each elected as directors of the Company to serve until the next annual meeting of shareholders.

 

The shareholders approved an amendment to the Company’s Articles of Incorporation, as amended to date, to increase the total number of shares of the Company’s authorized common stock to 75,000,000, on a post-reverse stock split basis.

 

The shareholders ratified an amendment to the Company’s Amended and Restated 2021 Stock Incentive Plan.

 

The shareholders also ratified the appointment of WithumSmith+Brown, P.C. as the independent registered public accounting firm for the fiscal year ending on December 31, 2022.

 

The shareholders voted in favor of the non-binding advisory proposal that the preferred frequency of stockholder advisory votes on executive compensation, referred to as “say-on-frequency,” be approved for every one year.

 

The final voting results on these matters were as follows:

 

1. Election of Directors:

 

Name  Votes For   Votes Withheld   Broker Non-Votes 
David Barthel   19,637,511    1,301,442    25,287 
Terry Brostowin, Esq.   19,631,511    1,307,442    25,287 
Dr. William Hearl   19,332,511    1,606,442    25,287 
Julie Kampf   18,313,011    2,625,942    25,287 
Dr. Vithalbhai Dhaduk   18,313,011    2,625,942    25,287 
Michael Stewart   19,332,511    1,606,442    25,287 
Dr. Nilesh Patel   18,613,011    2,325,942    25,287 

 

2. Approval of the Amendment to the Company’s Articles of Incorporation, as Amended to Date, to Increase the Total Number of Shares of Authorized Common Stock to 75,000,000 on a Post-Reverse Stock Split Basis:

 

Votes For   Votes Against   Votes Abstained   Broker Non-Votes 
 19,657,460    1,306,780    N/A    N/A 

 

3. Ratification of the Amendment to the Company’s Amended and Restated 2021 Stock Incentive Plan:

 

Votes For   Votes Against   Votes Abstained   Broker Non-Votes 
 19,655,942    1,308,298    N/A    N/A 

 

4. Ratification of the Appointment of WithumSmith+Brown PC as Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2022:

 

Votes For   Votes Against   Votes Abstained   Broker Non-Votes 
 20,964,233    1    6    N/A 

 

5. Non-Binding Advisory Vote on Preferred Frequency of Stockholder Advisory Votes on Executive Compensation, referred to as “Say-On-Frequency”:

 

One Year   Two Years   Three Years   Votes Abstained   Broker Non-Votes 
 12,633,459    7,619,934    680,559    5,001    25,287 

 

In light of the results of the “say-on-frequency” vote and other factors, the Board of Directors has determined that the Company will hold future advisory votes on the compensation of its named executive officers on an annual basis until the next “say-on-frequency” vote is conducted or until the Board of Directors determines that it is in the best interest of the Company to hold such votes with a different frequency. The next advisory vote regarding the frequency of say on frequency votes is required to occur no later than the Company’s 2028 Annual Meeting of Shareholders.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, Marizyme, Inc. has duly caused this current report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: April 26, 2023 MARIZYME, INC.
     
  By: /s/ David Barthel
    David Barthel
    Chief Executive Officer

 

 

 

Marizyme (QB) (USOTC:MRZM)
Gráfica de Acción Histórica
De Abr 2024 a May 2024 Haga Click aquí para más Gráficas Marizyme (QB).
Marizyme (QB) (USOTC:MRZM)
Gráfica de Acción Histórica
De May 2023 a May 2024 Haga Click aquí para más Gráficas Marizyme (QB).